Lung cancer remains the malignancy with the highest mortality and second highest incidence in both men and women within the United States. Image-guided ablative therapies are safe and effective for localized control of unresectable liver, renal, bone, and lung tumors. Local ablative therapies have been shown to slow disease progression and prolong disease-free survival in patients who are not surgical candidates, either due to local extent of disease or medical comorbidities. Commonly encountered complications of percutaneous ablation of lung tumors include pneumothorax, pleural inflammation, pleural effusions, and pneumonia, which are usually easily managed. This review will discuss the merits of image-guided ablation in the treatment of lung tumors and the underlying mechanism, procedural techniques, clinical utility, toxicity, imaging of tumor response, and future developments, with a focus on radiofrequency ablation.
*Department of Radiology, Bridgeport Hospital, Yale New Haven Health System
†Department of Radiology, St Vincent’s Medical Center, Bridgeport, CT
‡Department of Radiology, Montefiore Medical Center, Bronx, NY
Disclosure: There is no conflict of interest or other disclosures.
Reprints: Murthy R. Chamarthy, MD, Department of Radiology, Bridgeport Hospital, Yale New Haven Health System, 267 Grant St, Bridgeport, CT 06010 (e-mail: email@example.com).
Received December 9, 2012
Accepted August 21, 2013